BMJ (Clinical research ed.)
Audio Summaries

Home based, tailored intervention to reduce rate of falls after stroke (FAST): randomised trial

Mar 24, 2026

The study aimed to evaluate the effectiveness of a multidisciplinary, home-based intervention in reducing falls among community-dwelling individuals who have experienced a stroke. Results indicated that the intervention led to a significant 33% reduction in the rate of falls over 12 months, alongside improvements in self-efficacy, mobility, community participation, and balance. These findings suggest that tailored interventions can effectively mitigate fall risks in this population.

Effect of a clinical decision support system on stroke care quality and outcomes in patients with acute ischaemic stroke (GOLDEN BRIDGE II): cluster randomised clinical trial

Mar 20, 2026

The authors aimed to evaluate the effectiveness of a clinical decision support system (CDSS) on the quality of stroke care and clinical outcomes in patients with acute ischaemic stroke. The study, conducted across 77 hospitals in China, found that the CDSS significantly reduced new vascular events at three months and improved care quality compared to usual care, without increasing the risk of bleeding or affecting disability and mortality rates.

Accuracy of glomerular filtration rate estimation based on creatinine and cystatin C for monitoring moderate chronic kidney disease in adults: prospective, longitudinal cohort study

Mar 19, 2026

The authors aimed to evaluate the longitudinal accuracy of glomerular filtration rate (GFR) estimating equations that incorporate both creatinine and cystatin C for monitoring moderate chronic kidney disease (CKD) in adults. Their findings indicate that dual biomarker equations provided better agreement with measured GFR changes compared to those based solely on creatinine, although all equations exhibited poor sensitivity for detecting disease progression. The study suggests that incorporating both biomarkers in clinical practice could enhance monitoring and management of CKD.

New and emerging treatments for anxiety disorders

Mar 16, 2026

The authors aim to identify and evaluate new and emerging treatments for anxiety disorders, addressing the limitations of standard therapies due to non-response and relapse rates. The review highlights various novel stand-alone treatments, such as innovative psychotherapies, neuromodulation techniques, and pharmacological agents, as well as augmentation strategies designed to enhance exposure therapy. While many of these treatments show promise, further testing is needed for some before clinical implementation.

Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial

Mar 16, 2026

The authors of the phase 3 PHILA trial aimed to evaluate the efficacy and safety of pyrotinib, in combination with trastuzumab and docetaxel, compared to placebo in patients with untreated HER2 positive metastatic breast cancer. The updated results demonstrated that the pyrotinib regimen significantly improved both progression-free survival and overall survival, while maintaining a consistent safety profile. These findings support the use of this dual anti-HER2 treatment strategy as an effective initial therapy for this patient population.

Camrelizumab plus CAPOX with camrelizumab based maintenance versus CAPOX alone as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma: randomised phase 3 trial

Mar 12, 2026

This phase 3 trial aimed to compare the effectiveness of camrelizumab combined with capecitabine and oxaliplatin (CAPOX) followed by maintenance therapy with either apatinib or camrelizumab against CAPOX alone in patients with HER2-negative, unresectable gastric or gastro-oesophageal junction adenocarcinoma. The results indicated that the camrelizumab-based regimens significantly improved overall survival compared to CAPOX alone, although no additional survival benefit was observed when apatinib was added during maintenance, and higher rates of severe treatment-related adverse events were noted.